Exchange: NYSE·Updated 07:30 PM EDT

STVN News

News
all
press releases
Stevanato Group is Now Oversold (STVN)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
Stevanato Group is Now Oversold (STVN)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
More News
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Stevanato Group to Participate in Two Upcoming Investor Conferences
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at...
Business Wire
Chief Financial Officer At Stevanato Group Sells $84K Of Stock
Revealing a significant insider sell on August 10, Marco Lago Dal, Chief Financial Officer at Stevanato Group (NYSE:STVN), as per the latest SEC filing. What Happened: Dal's recent Form 4 filing with the U.S.read more...
Benzinga
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +6.67% and -0.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights...
Business Wire
Liraglutide Combination Products Incorporating Stevanato Group's Alina Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Groups proprietary Alina...
Business Wire
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +51.69% and +40.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.